All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Sanofi's Qfitlia (fitusiran) and Cablivi (caplacizumab) receive China approval for rare hematologic diseases
Protein therapy, hematologic disorders, nanobody, hemophilia, siRNA therapy, thrombotic thrombocytopenic purpura - Read more

GSK's Blujepa (gepotidacin) wins FDA approval for uncomplicated urogenital gonorrhoea treatment following Ph3 success
Small molecule, infectious disease, antibiotic, gonorrhoea, Neisseria gonorrhoeae - Read more

Amgen's Uplizna (inebilizumab) wins FDA approval for generalized myasthenia gravis targeting CD19-positive B cells
Antibody, autoimmune, monoclonal antibody, myasthenia gravis, CD19 target, B cell depletion - Read more

THE GOOD
Business Development & Partnerships

Zealand Pharma, OTR Therapeutics partner on metabolic disease therapeutics, $20M upfront, $2.5B milestones
Licensing deal, metabolic disorders, small molecule, milestone payments - Read more

Indivumed, URMC launch joint venture for patient-centric cancer therapeutics development focusing on solid tumors
Joint venture, oncology, research collaboration, biosamples - Read more

Xcell Biosciences, Culture Biosciences partner to advance cell therapy quality through AI and machine learning
Research collaboration, cell therapy, AI/ML, manufacturing - Read more

Tahoe Therapeutics, Parse Biosciences partner on 300M single cell sequencing project using GigaLab platform
Research collaboration, AI/ML, drug discovery, single cell sequencing - Read more

Everest Medicines, Hasten enter commercialization services and licensing agreements for PCSK9 inhibitor Lerodalcibep
Licensing deal, commercialization, cardiovascular, small molecule, PCSK9 inhibitor - Read more

Basilea, Phare Bio partner on AI-driven antibiotic discovery, success-based payments
Research collaboration, infectious disease, AI/ML, small molecule, milestone payments - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Eli Lilly's retatrutide (triple hormone receptor agonist) achieves 26.6% weight loss in Ph3 obesity trial
Small molecule, metabolic, GLP-1 receptor agonist, obesity, knee osteoarthritis, triple hormone receptor agonist - Read more

Genfit reports positive Ph1b data for GNS561 plus MEK inhibitor combo in cholangiocarcinoma patients
Small molecule, cancer, autophagy inhibitor, cholangiocarcinoma, KRAS mutation, combination therapy - Read more

AC Immune's ACI-7104.056 shows promising Ph2 results slowing Parkinson's disease progression via alpha-synuclein targeting
Immunotherapy, neurological, active immunotherapy, Parkinson's disease, alpha-synuclein target - Read more

Rhythm Pharmaceuticals' Imcivree (setmelanotide) shows promise in Ph2 Prader-Willi syndrome trial, advancing to Ph3
Small molecule, neurological, MC4R agonist, Prader-Willi syndrome, obesity, hyperphagia - Read more

Corbus Pharmaceuticals reports positive Ph1a results for CRB-913 (CB1 inverse agonist) demonstrating weight loss in obesity
Small molecule, obesity, CB1 inverse agonist, metabolic, chronic obesity management - Read more

THE GOOD
Company Launches

Aukera Therapeutics emerges from stealth with CHF 4.5M ($5.63M) funding for neurological RAPTOR inhibitor development
Small molecule, neurological, rare disease, strategic, investment - Read more

THE GOOD
Fundraises

Prolynx raises $70M Series A, longer-lasting obesity drugs with less frequent dosing
Obesity, extended-release technology, incretin drugs, platform technology - Read more

DISCO Pharmaceuticals raises $42M seed, surfaceome-targeted ADC oncology programs advancing
Oncology, antibody-drug conjugates, surfaceome mapping, platform technology, preclinical - Read more

Immunovant raises $550M common stock offering, autoimmune disease clinical-stage immunology company
Clinical-stage, autoimmune, immunology, antibody - Read more

Medra raises $52M Series A, automated AI drug discovery platform integration
AI/ML platform, drug discovery, platform technology, robotics, AI-driven - Read more

Wake Forest University School of Medicine receives $3.8M NIH grant to test precision septic-shock therapy
Small molecule, infectious disease, septic shock, angiotensin II, precision medicine, renin-angiotensin system - Read more

Starton Holdings raises $40M IPO, Phase 2 controlled release cancer formulations
Oncology, controlled release formulations, hematologic malignancies, clinical-stage, platform technology - Read more

Allegria Therapeutics raises $5.1M seed extension for mast cell-mediated disease therapeutics
Autoimmune, mast cell modulation, preclinical, inflammatory conditions - Read more

Relation raises $26M additional funding, expanding AI-driven drug development operations
Immunology, AI/ML platform, metabolic disease, bone diseases, platform-enabled - Read more

THE GOOD
Investments

Tjoapack expands US packaging operations with new 170,000-sq.-ft. Tennessee facility opening 2027
Multiple modalities, operational, major investment, manufacturing expansion - Read more

THE GOOD
Regulatory

European legislators agree on major pharma policy overhaul reducing drug exclusivity periods, strengthening supply chains
Regulatory, rare disease, strategic, operational - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Rezolute's ersodetug (anti-glucagon receptor antibody) fails Ph3 trial for congenital hyperinsulinism hypoglycemia treatment
Antibody, metabolic, monoclonal antibody, congenital hyperinsulinism, hypoglycemia, ersodetug - Read more

THE BAD
Layoffs

Geron Corporation cuts one-third of workforce to reduce operating costs after recent approval
Cell therapy, oncology, operational, cost reduction - Read more

THE BAD
Politics & Policy

House passes diluted Biosecure Act in defense bill, restricting federal contracts with Chinese biotech suppliers
Regulatory, strategic, operational, competitive - Read more [Paywall]

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here